首页> 中文期刊> 《中国药理学报:英文版》 >Amyloid beta: structure, biology and structure-based therapeutic development

Amyloid beta: structure, biology and structure-based therapeutic development

         

摘要

Amyloid beta peptide (Aβ) is produced through the proteolytic processing of a transmembrane protein,amyloid precursor protein (APP),by β-and Y-secretases.Aβ accumulation in the brain is proposed to be an early toxic event in the pathogenesis of Alzheimer's disease,which is the most common form of dementia associated with plaques and tangles in the brain.Currently,it is unclear what the physiological and pathological forms of Aβ are and by what mechanism Aβ causes dementia.Moreover,there are no efficient drugs to stop or reverse the progression of Alzheimer's disease.In this paper,we review the structures,biological functions,and neurotoxicity role of Aβ.We also discuss the potential receptors that interact with Aβ and mediate Aβ intake,clearance,and metabolism.Additionally,we summarize the therapeutic developments and recent advances of different strategies for treating Alzheimer's disease.Finally,we will report on the progress in searching for novel,potentially effective agents as well as selected promising strategies for the treatment of Alzheimer's disease.These prospects include agents acting on Aβ,its receptors and tau protein,such as small molecules,vaccines and antibodies against Aβ;inhibitors or modulators of ββ-and γ-secretase;Aβ-degrading proteases;tau protein inhibitors and vaccines;amyloid dyes and microRNAs.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号